NASDAQ:AMRN Amarin (AMRN) Stock Price, News & Analysis $16.22 +0.51 (+3.25%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Amarin Stock (NASDAQ:AMRN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Amarin alerts:Sign Up Key Stats Today's Range$15.91▼$16.6050-Day Range$9.55▼$16.1952-Week Range$7.08▼$18.00Volume170,121 shsAverage Volume81,484 shsMarket Capitalization$335.92 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingSell Company OverviewAmarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Read More… Amarin Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks15th Percentile Overall ScoreAMRN MarketRank™: Amarin scored higher than 15% of companies evaluated by MarketBeat, and ranked 891st out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingAmarin has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageAmarin has only been the subject of 1 research reports in the past 90 days.Read more about Amarin's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Amarin are expected to decrease in the coming year, from ($0.15) to ($0.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amarin is -4.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amarin is -4.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmarin has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Amarin's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.08% of the float of Amarin has been sold short.Short Interest Ratio / Days to CoverAmarin has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Amarin has recently decreased by 13.81%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAmarin does not currently pay a dividend.Dividend GrowthAmarin does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.08% of the float of Amarin has been sold short.Short Interest Ratio / Days to CoverAmarin has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Amarin has recently decreased by 13.81%, indicating that investor sentiment is improving significantly. News and Social Media3.2 / 5News Sentiment0.81 News SentimentAmarin has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Amarin this week, compared to 2 articles on an average week.Search Interest5 people have searched for AMRN on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows2 people have added Amarin to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Amarin insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.96% of the stock of Amarin is held by insiders.Percentage Held by InstitutionsOnly 22.25% of the stock of Amarin is held by institutions.Read more about Amarin's insider trading history. Receive AMRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amarin and its competitors with MarketBeat's FREE daily newsletter. Email Address AMRN Stock News HeadlinesZacks Research Has Bullish Forecast for Amarin Q3 EarningsJune 28 at 2:07 AM | americanbankingnews.comAmarin (AMRN) Soars 27.3%: Is Further Upside Left in the Stock? - NasdaqJune 27 at 5:06 PM | nasdaq.comI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.June 30 at 2:00 AM | Porter & Company (Ad)The Goldman Sachs Group Forecasts Strong Price Appreciation for Amarin (NASDAQ:AMRN) StockJune 27 at 2:29 AM | americanbankingnews.comAmarin, Recordati Ink Exclusive License, Supply Deal to Commercialize VazkepaJune 24, 2025 | marketwatch.comAmarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in EuropeJune 24, 2025 | finance.yahoo.comAmarin Stock Surges 11% After $25 Million Licensing Deal with RecordatiJune 24, 2025 | msn.comAmarin inks licensing deal with Recordati for lead drug VazkepaJune 24, 2025 | msn.comSee More Headlines AMRN Stock Analysis - Frequently Asked Questions How have AMRN shares performed this year? Amarin's stock was trading at $9.70 on January 1st, 2025. Since then, AMRN stock has increased by 67.8% and is now trading at $16.28. View the best growth stocks for 2025 here. How were Amarin's earnings last quarter? Amarin Corporation PLC (NASDAQ:AMRN) announced its quarterly earnings results on Wednesday, May, 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.02. Amarin had a negative net margin of 41.07% and a negative trailing twelve-month return on equity of 17.21%. Read the conference call transcript. When did Amarin's stock split? Amarin's stock reverse split before market open on Friday, April 11th 2025.The 1-20 reverse split was announced on Wednesday, March 12th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 10th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. Does Amarin have any subsidiaries? The following companies are subsidiaries of Amarin: Ester Neurosciences, Amarin France SAS, Amarin Germany GmbH, Amarin Italy S.r.l, Amarin Pharmaceuticals Ireland Limited, Amarin Pharma Inc., Amarin Switzerland GmbH, Amarin UK Limited, and Ester Neurosciences Limited. How do I buy shares of Amarin? Shares of AMRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Amarin own? Based on aggregate information from My MarketBeat watchlists, some other companies that Amarin investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities () and Sterne Agee CRT (). Company Calendar Last Earnings5/07/2025Today6/30/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AMRN CIK897448 Webwww.amarincorp.com Phone(531) 669-9020FaxN/AEmployees360Year Founded1991Price Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside-25.9%Consensus RatingSell Rating Score (0-4)1.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$82.18 million Net Margins-41.07% Pretax Margin-38.38% Return on Equity-17.21% Return on Assets-12.16% Debt Debt-to-Equity RatioN/A Current Ratio3.53 Quick Ratio2.55 Sales & Book Value Annual Sales$228.61 million Price / Sales1.47 Cash FlowN/A Price / Cash FlowN/A Book Value$23.62 per share Price / Book0.69Miscellaneous Outstanding Shares20,710,000Free Float20,301,000Market Cap$335.21 million OptionableOptionable Beta0.71 Social Links A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:AMRN) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amarin Corporation PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Amarin With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.